Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 8/20 | 0.64 |
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7439474 | 0.91 | AR (0.60) | ARMAPTGAASMN1; SMN2MEN1 | |
| SCHEMBL276059 | 0.85 | AR (0.56) | ARMAPTGAASMN1; SMN2MEN1 | |
| SCHEMBL276472 | 0.85 | MAPT (0.58) | ARMAPTGAASMN1; SMN2MEN1 | |
| SCHEMBL276917 | 0.85 | AR (0.59) | ARMAPTGAASMN1; SMN2MEN1 | |
| SCHEMBL30741020 | 0.81 | AR (0.51) | ARMAPTGAASMN1; SMN2RAB9A | |
| SCHEMBL276323 | 0.79 | AR (0.56) | ARMAPTGAASMN1; SMN2RAB9A | |
| SCHEMBL4779958 | 0.79 | AR (0.56) | ARMAPTGAASMN1; SMN2MEN1 | |
| SCHEMBL30740973 | 0.79 | AR (0.48) | ARMAPTGAASMN1; SMN2MEN1 | |
| SCHEMBL2903730 | 0.78 | AR (1.00) | ARMAPTGAASMN1; SMN2MEN1 | |
| SCHEMBL2659125 | 0.78 | MAPT (0.56) | ARMAPTSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2465505-A1 | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | Bayer HealthCare LLC (US) | 2012-06-20 | — | — | EP | disclosed |